The present invention relates to a method for producing a formic acid including, a first step of allowing carbon dioxide and hydrogen to react with each other in a solution containing a solvent and a catalyst dissolved in the solvent and in the presence of an amine insoluble in the solvent, and allowing a generated formic acid to adsorb to the amine, in which the catalyst contains at least one metal element selected from the group consisting of metal elements belonging to Groups 8, 9, and 10 of a periodic table and the amine is an amine immobilized on a solid.

The present invention relates to a method for producing a formic acid including, a first step of allowing carbon dioxide and hydrogen to react with each other in a solution containing a solvent and a catalyst dissolved in the solvent and in the presence of an amine insoluble in the solvent, and allowing a generated formic acid to adsorb to the amine, in which the catalyst contains at least one metal element selected from the group consisting of metal elements belonging to Groups 8, 9, and 10 of a periodic table and the amine is an amine immobilized on a solid.

A method for generating a carboxylic acid from carbon dioxide (CO.sub.2), the method includes (a) feeding a gas stream having the CO.sub.2 to a first reactor having a base (MOH) to produce bicarbonate (MHCO.sub.3) and (b) feeding the MHCO.sub.3 generated in the first reactor to a second reactor disposed downstream from the first reactor. The second reactor includes a catalyst. The method also includes (c) contacting the MHCO.sub.3 with hydrogen gas in the presence of the catalyst in the second reactor to produce formate (HCOOM) and (d) electrolysing an aqueous solution of a metal halide (MCl) in a chloro-alkali electrolysis reactor fluidly coupled to the first reactor, the second reactor, or both to produce at least a portion of the MOH, the hydrogen gas and Cl.sub.2. The portion of the MOH is used in step (a) and the carboxylic acid is formic acid (HCOOH).

A method for generating a carboxylic acid from carbon dioxide (CO.sub.2), the method includes (a) feeding a gas stream having the CO.sub.2 to a first reactor having a base (MOH) to produce bicarbonate (MHCO.sub.3) and (b) feeding the MHCO.sub.3 generated in the first reactor to a second reactor disposed downstream from the first reactor. The second reactor includes a catalyst. The method also includes (c) contacting the MHCO.sub.3 with hydrogen gas in the presence of the catalyst in the second reactor to produce formate (HCOOM) and (d) electrolysing an aqueous solution of a metal halide (MCl) in a chloro-alkali electrolysis reactor fluidly coupled to the first reactor, the second reactor, or both to produce at least a portion of the MOH, the hydrogen gas and Cl.sub.2. The portion of the MOH is used in step (a) and the carboxylic acid is formic acid (HCOOH).

The present invention provides methods and uses of inhibitors of histone deacetylase 11 (HDAC11) in the treatment of diseases and/or disorders, such as, for example, cell proliferative diseases.

The present invention provides methods and uses of inhibitors of histone deacetylase 11 (HDAC11) in the treatment of diseases and/or disorders, such as, for example, cell proliferative diseases.

The present disclosure relates to crystalline forms of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium salts having high solubility. The disclosure also relates to use of said crystalline forms in medicine.

The present invention generally relates to novel synthetic methods, systems, kits, salts, and precursors useful in medical imaging. In some embodiments, the present invention provides compositions comprising an imaging agent precursor, which may be formed using the synthetic methods described herein. An imaging agent may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in .sup.18F. In some cases, an imaging agent including salt forms (e.g., ascorbate salt) may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.

The present invention generally relates to novel synthetic methods, systems, kits, salts, and precursors useful in medical imaging. In some embodiments, the present invention provides compositions comprising an imaging agent precursor, which may be formed using the synthetic methods described herein. An imaging agent may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in .sup.18F. In some cases, an imaging agent including salt forms (e.g., ascorbate salt) may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.

Some embodiments of the invention include methods of using a compound (e.g., Formula (I)) for the reduction of carbon dioxide to formate by contacting the carbon dioxide with a composition comprising a compound. In certain embodiments, the source of the carbon dioxide is air or is flue gas. Additional embodiments of the invention are also discussed herein.